Market News

0 0 0

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

FUJIY Q1 Earnings Fall Y/Y on Bio CDMO Costs, Revenues Rise

FUJIFILM's Q1 revenue hit a record yen 826.5 billion, but earnings fell 30% as Bio CDMO costs and restructuring weighed on profitability.

Related Symbols 1

F FUJIY FUJIY

Source: Zacks Investment Research

0 0 0

Source: CNBC News Agency

1 month ago

Stock Medium Importance

Shares of this digital medical platform were up more than 100% at one point. Here's what's driving it

Doximity had a solid first quarter and raised its full year revenue guidance. But AI search isn't baked into these forecasts, analysts believe, and it's bringing in 10 times the revenue it costs to run, the CEO revealed on the conference call.

Related Symbols 1

D DOCS DOCS

Source: CNBC

0 0 0

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

Construction Partners (ROAD) Q3 Earnings and Revenues Surpass Estimates

Construction Partners (ROAD) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $0.81 per share a year ago.

Related Symbols 1

R ROAD ROAD

Source: Zacks Investment Research

0 0 0

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.28 per share a year ago.

Related Symbols 1

T TMCI TMCI

Source: Zacks Investment Research

0 0 0

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.27 per share a year ago.

Related Symbols 1

R RPID RPID

Source: Zacks Investment Research

0 0 0

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

Starz Entertainment Corp. (STRZ) Reports Q2 Loss, Tops Revenue Estimates

Starz Entertainment Corp. (STRZ) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $2.23 per share a year ago.

Related Symbols 1

S STRZ STRZ

Source: Zacks Investment Research

0 0 0

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

ARKO Corp. (ARKO) Q2 Earnings Lag Estimates

ARKO Corp. (ARKO) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.16 per share a year ago.

Related Symbols 1

A ARKO ARKO

Source: Zacks Investment Research

0 0 0

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.02 per share a year ago.

Related Symbols 1

G GYRE GYRE

Source: Zacks Investment Research

0 0 0

Source: Zacks Investment Research News Agency

1 month ago

Stock Medium Importance

Johnson Outdoor (JOUT) Q3 Earnings and Revenues Top Estimates

Johnson Outdoor (JOUT) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.75 per share a year ago.

Related Symbols 1

J JOUT JOUT

Source: Zacks Investment Research

0 0 0

Source: Newsfile Corp News Agency

1 month ago

Stock Medium Importance

MONDAY DEADLINE: Berger Montague Advises ADMA Biologics, Inc. (ADMA) Investors to Inquire About a Securities Fraud Class Action by August 10, 2026

Philadelphia, Pennsylvania--(Newsfile Corp. - August 7, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company") on behalf of investors who purchased or acquired ADMA common stock during the period from August 9, 2024 through March 25, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired ADMA securities during the Class Period may, no later than August 10, 2026, seek to be appointed as a lead plaintiff representative of the class.

Related Symbols 1

A ADMA ADMA

Source: Newsfile Corp

0 0 0

Source: Seeking Alpha News Agency

1 month ago

Stock Medium Importance

TPG RE Finance Trust: We Continue To Find The Series C Preferred Shares Attractive

TPG Real Estate Finance Trust (TRTX) Series C Preferred (TRTX.PR.C) remains a Buy, supported by robust Q2 2026 financials and prudent portfolio management. TRTX has reduced office exposure to 4.3% and shifted toward multifamily and industrial assets, mitigating sector risk. Leverage increased to 3.3x, balanced by conservative underwriting and a capital structure reset with long-term, non-mark-to-market debt.

Related Symbols 1

T TPG TPG

Source: Seeking Alpha

0 0 0